摘要
肺癌已经成为威胁人类健康的重要疾病之一,非小细胞肺癌(non-small cell lung cancer,NSCLC)是其重要的病理类型,对于不可手术的驱动基因阴性的晚期NSCLC患者来说,一般先采用同步放化疗,但部分患者易出现治疗不耐受及疾病进展的情况。免疫治疗的出现为解决这一难题提供了新思路,但单纯免疫治疗起效慢、易出现耐药,因此各种联合治疗的研究正在不断开展,文章就免疫治疗、放疗、以及免疫联合放疗的研究进展进行综述。
Lung cancer has become one of the important causes of threats to human health,and non-small cell lung cancer(NSCLC)is an important pathological type.For inoperable driver gene-negative patients with advanced NSCLC,concurrent chemoradiotherapy is generally used first,but some patients are prone to intolerance and disease progression.The emergence of immunotherapy has provided new ideas to solve this problem in lung cancer.However,immunotherapy monotherapy is less effective and prone to drug resistance.Therefore,various combination therapies are being researched.The research progress of immunotherapy,radiotherapy,and immunotherapy combined with radiotherapy were reviewed.
作者
王静宜
孙岚
李小青
邱丹
Wang Jingyi;Sun Lan;Li Xiaoqing;Qiu Dan(Department of Oncology,Bishan Hospital of Chongqing Medical University,Chongqing 402760,China)
出处
《国际免疫学杂志》
CAS
2023年第2期180-183,共4页
International Journal of Immunology
基金
北京科创医学发展基金会(KC2021-JX-0186-28)。
